Skip to main content

Advertisement

Log in

Selektive Hemmung der T-Zell-Aktivierung durch das Fusionsprotein CTLA4Ig als neues Therapieprinzip für die RA

Referierte Originalarbeit: Kremer JM, Westhovens R, Leon M, Di Giorgio E, Alten R et al (2003) Treatment of Rheumatoid Arthritis by Selective Inhibiton of T-Cell Activation with Fusion Protein CTLA4Ig. N Engl J Med 349:1907–1915

Selective inhibition of T-cell-activation with fusion protein CTLA4lg—a new treatment option for rheumatoid arthritis

  • KLINISCHE STUDIEN KURZGEFASST
  • Published:
Zeitschrift für Rheumatologie Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Grohmann U, Orabona C, Fallarino F et al (2002) CTLA-4-Ig regulates tryptophancatabolism in vivo. Nat Immunol 3:1097–1101

    Google Scholar 

  2. Moreland L, Alten R, van den Bosch F et al (2002) Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum 46:1470–1479

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to K. Krüger.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Krüger, K. Selektive Hemmung der T-Zell-Aktivierung durch das Fusionsprotein CTLA4Ig als neues Therapieprinzip für die RA. Z. Rheumatol. 64, 40–41 (2005). https://doi.org/10.1007/s00393-005-0620-0

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00393-005-0620-0

Navigation